EXPLORINEER
en

Archive — US — techcrunch

Varda says it has proven space manufacturing works — now it wants to make itboring

Varda Space Industries aims to revolutionize pharmaceutical manufacturing by using microgravity to produce drugs more efficiently. CEO Will Bruey envisions a future where space deliveries of medications become routine, making it cheaper to send humans to orbit for pharmaceutical production than for earthly living. Varda's recent success includes returning pharmaceuticals from orbit, highlighting the potential for commercial viability in space.

Key points

  • Varda has successfully manufactured pharmaceuticals in space, demonstrating microgravity's advantages in drug crystallization.
  • In February 2024, it became only the third organization to return substances from space, marking a pivotal achievement in commercial space operations.
  • The company uses small capsules for transport, capable of high-speed reentry, with plans for regular pharmaceutical manufacturing runs in orbit.
  • Varda's business model contrasts with traditional satellite companies, as it requires constant launches based on demand for drug production, which could drive down launch costs over time.
  • The success of Varda hinges on regulatory approval and commercial viability, as no space-manufactured drugs are yet available on the market.

Why it matters

  • The advancements made by Varda are reflective of the ongoing trend in 2025 IT towards commercialization of space, enabling regular business operations in low Earth orbit.
  • Historical context shows that companies like SpaceX have set precedents for reusability and cost efficiency in space travel, which Varda aims to exploit.
  • The pharmaceutical industry often seeks innovation in drug production; Varda’s approach resonates with trends in manufacturing technology and supply chain evolution.

Varda's innovative approach to space-based pharmaceutical production could transform the industry, making space manufacturing more accessible and economically viable, provided the necessary regulatory and commercial hurdles are overcome.